Abbott Launches FDA-Approved CRC Blood Test with Medicare Coverage
ABT sits 23% above its 52-week low of $81.97.
Summary
Abbott has commercially launched SimpleScreen CRC, its FDA-approved blood-based colorectal cancer screening test for average-risk adults 45+. The test, developed by Freenome and exclusively commercialized by Abbott, demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity, with Medicare coverage under Part B and no out-of-pocket costs for patients. This follows the FDA approval announced on August 3, 2026, and adds key performance and reimbursement details that support clinician adoption. The large addressable population of unscreened adults and Medicare reimbursement lower barriers to uptake, positioning Abbott to capture share in the growing blood-based CRC screening market. Watch for early commercial traction and any expansion of payer coverage beyond Medicare.
At the time of this announcement, ABT was trading at $101.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.7B. The 52-week trading range was $81.97 to $135.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.